Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Biogen Seals Two Neurology Deals

by Lisa M. Jarvis
September 16, 2013 | A version of this story appeared in Volume 91, Issue 37

Biogen Idec is handing over $100 million as part of a six-year neurology drug development pact with Isis Pharmaceuticals. Isis will grant Biogen exclusive rights to use its antisense technology to develop treatments for neurological diseases. The companies will jointly validate disease targets; Isis will be responsible for discovering antisense therapies, and Biogen will take the lead on finding small-molecule and biologic drugs. In a separate neurology drug deal, Biogen and Amicus Therapeutics will develop small molecules targeting the lysosomal enzyme glucocerobrosidase for the treatment of Parkinson’s disease.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.